BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lasagna A, Zuccaro V, Sacchi P, Chiellino S, Bruno R, Pedrazzoli P. Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons? Future Oncol 2021;17:1577-80. [PMID: 33590770 DOI: 10.2217/fon-2020-1196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lasagna A, Albi G, Maserati R, Zuccarini A, Quaccini M, Baldanti F, Sacchi P, Bruno R, Pedrazzoli P. Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1044098] [Reference Citation Analysis]
2 Lasagna A, Arlunno B, Imarisio I. A case report of pulmonary nocardiosis during pembrolizumab: the emerging challenge of the infections on immunotherapy. Immunotherapy 2022;14:1369-75. [PMID: 36420679 DOI: 10.2217/imt-2022-0152] [Reference Citation Analysis]
3 Maepa MB, Ely A, Kramvis A, Bloom K, Naidoo K, Simani OE, Maponga TG, Arbuthnot P. Hepatitis B Virus Research in South Africa. Viruses 2022;14:1939. [DOI: 10.3390/v14091939] [Reference Citation Analysis]
4 Lasagna A, Cassaniti I, Sacchi P, Baldanti F, Bruno R, Pedrazzoli P. Infectious complications and immunotherapy: old pitfalls and new horizons. Future Oncol 2022. [PMID: 35678614 DOI: 10.2217/fon-2022-0277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]